Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

  1. Anna L. McNaughton
  2. Robert S. Paton
  3. Matthew Edmans
  4. Jonathan Youngs
  5. Judith Wellens
  6. Prabhjeet Phalora
  7. Alex Fyfe
  8. Sandra Belij-Rammerstorfer
  9. Jai S. Bolton
  10. Jonathan Ball
  11. George W. Carnell
  12. Wanwisa Dejnirattisai
  13. Christina Dold
  14. David W. Eyre
  15. Philip Hopkins
  16. Alison Howarth
  17. Kreepa Kooblall
  18. Hannah Klim
  19. Susannah Leaver
  20. Lian Ni Lee
  21. César López-Camacho
  22. Sheila F. Lumley
  23. Derek C. Macallan
  24. Alexander J. Mentzer
  25. Nicholas M. Provine
  26. Jeremy Ratcliff
  27. Jose Slon-Compos
  28. Donal Skelly
  29. Lucas Stolle
  30. Piyada Supasa
  31. Nigel Temperton
  32. Chris Walker
  33. Beibei Wang
  34. Duncan Wyncoll
  35. Peter Simmonds
  36. Teresa Lambe
  37. John Kenneth Baillie
  38. Malcolm G. Semple
  39. Peter J.M. Openshaw
  40. Uri Obolski
  41. Marc Turner
  42. Miles Carroll
  43. Juthathip Mongkolsapaya
  44. Gavin Screaton
  45. Stephen H. Kennedy
  46. Lisa Jarvis
  47. Eleanor Barnes
  48. Susanna Dunachie
  49. José Lourenço
  50. Philippa C. Matthews
  51. Tihana Bicanic
  52. Paul Klenerman
  53. Sunetra Gupta
  54. Craig P. Thompson

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1172/jci.insight.156372
  2. ScreenIT

    SciScore for 10.1101/2021.05.04.21256571: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: SNBTS blood donors gave fully informed consent to virological testing, donation was made under the SNBTS Blood Establishment Authorisation and the study was approved by the SNBTS Research and Sample Governance Committee IRAS project number 18005.
    IRB: Ethical approval was given by the South Central - Oxford C Research Ethics Committee in England (Ref: 13/SC/0149) and by the Scotland A Research Ethics Committee (Ref: 20/SS/0028).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    BlindingResearchers working with the samples in the laboratory were blinded to the clinical outcomes of the ICU patients during testing.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Enzyme-linked immunosorbent assay: SARS-CoV-2 spike, RBD as well as HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43 spike IgG antibody responses were measured using ELISAs.
    HCoV-OC43 spike IgG
    suggested: None
    Secondary antibody rabbit anti-human whole IgG conjugated to alkaline phosphatase (Sigma, USA) was added at a dilution of 1:1000 in casein–PBS solution and incubated for 1 hour at RT.
    Secondary antibody rabbit anti-human whole IgG
    suggested: None
    anti-human whole IgG
    suggested: None
    Protein sequences used in ELISAs: MSD V-PLEX assay: IgG antibody responses to SARS-CoV-2 spike, RBD, NTD and nucleocapsid and the spike proteins of SARS-CoV-1, HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43 were assessed using the Meso Scale Diagnostics (MSD) Multi-Spot Assay System (MSD, USA)
    HCoV-NL63
    suggested: None
    HCoV-HKU1
    suggested: None
    A 1x working concentration of the SULFO-TAG anti-human IgG Detection Antibody was prepared in Diluent 100.
    anti-human IgG
    suggested: (RevMAb Biosciences Cat# 31-1019-MK, RRID:AB_2783627)
    MSD ACE2 competition assay: The ability of antibodies present in serum/plasma to inhibit the binding of angiotensin-converting enzyme 2 (ACE2) to the SARS-CoV full-length spike proteins and RBD domains was assessed using the COVID-19 ACE2 competition assay (MSD, USA).
    ACE2
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    Enzyme-linked immunosorbent assay: SARS-CoV-2 spike, RBD as well as HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43 spike IgG antibody responses were measured using ELISAs.
    HCoV-NL63
    suggested: RRID:CVCL_RW88)
    HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43 spike antigens were bought from Sino Biological, China.
    HCoV-229E
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    ISRCTN51287266NANA

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.05.04.21256571v1 on medRxiv